This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
clinical signs | 1450 |
public health | 649 |
mg kg | 617 |
united states | 480 |
animal health | 479 |
lymph nodes | 372 |
guinea pigs | 354 |
naked mole | 349 |
may also | 347 |
infectious diseases | 326 |
animal models | 299 |
animal welfare | 296 |
wild animals | 281 |
virus infection | 278 |
bone marrow | 257 |
immune response | 252 |
may occur | 249 |
weight loss | 243 |
small ruminants | 239 |
respiratory disease | 236 |
human health | 232 |
laboratory animal | 225 |
mole rats | 220 |
infected animals | 213 |
respiratory syndrome | 212 |
cell lines | 205 |
respiratory tract | 204 |
differential diagnosis | 203 |
laboratory animals | 197 |
animal model | 197 |
veterinary medicine | 197 |
meat inspection | 189 |
affected animals | 179 |
body weight | 179 |
one health | 179 |
zoonotic diseases | 177 |
escherichia coli | 177 |
cell culture | 175 |
acute respiratory | 173 |
animals may | 167 |
immune system | 164 |
research complications | 164 |
clinical disease | 163 |
mole rat | 160 |
kg iv | 156 |
guinea pig | 156 |
infectious disease | 155 |
food safety | 153 |
severe acute | 152 |
domestic animals | 152 |
companion animals | 150 |
blood pressure | 149 |
animal products | 146 |
animal species | 146 |
gastrointestinal tract | 145 |
animal diseases | 143 |
small animal | 143 |
pg ml | 141 |
west nile | 139 |
immune responses | 137 |
doc id | 136 |
cord uid | 136 |
may cause | 135 |
blood flow | 134 |
septic shock | 133 |
heart rate | 129 |
infectious agents | 128 |
valley fever | 123 |
rift valley | 123 |
inflammatory response | 122 |
direct contact | 122 |
nipah virus | 121 |
ml kg | 121 |
farm animals | 118 |
nervous system | 118 |
avian influenza | 118 |
potency testing | 118 |
rhesus macaques | 117 |
risk factors | 117 |
peripheral blood | 116 |
human disease | 116 |
food chain | 114 |
may result | 114 |
ng ml | 113 |
laboratory mice | 113 |
respiratory syncytial | 112 |
respiratory distress | 111 |
body temperature | 111 |
see chapter | 110 |
bovine respiratory | 109 |
bovine viral | 109 |
renal failure | 108 |
differential diagnoses | 108 |
upper respiratory | 107 |
veal calves | 107 |
animal medicine | 106 |
commonly used | 104 |
syncytial virus | 104 |
wildlife trade | 104 |
mast cell | 104 |
blood samples | 103 |
physical examination | 103 |
acute phase | 102 |
risk assessment | 102 |
disease control | 102 |
north america | 101 |
vaccinated animals | 100 |
organ failure | 100 |
zoonotic disease | 100 |
antimicrobial resistance | 100 |
mucous membranes | 99 |
may develop | 98 |
wild animal | 98 |
may include | 98 |
clinical trials | 97 |
endothelial cells | 96 |
mouth disease | 95 |
veterinary vaccines | 94 |
viral infections | 92 |
blood cell | 91 |
lymph node | 91 |
hemolytic anemia | 91 |
commercially available | 91 |
influenza virus | 90 |
present study | 89 |
signs include | 89 |
see table | 89 |
middle east | 88 |
blood cells | 88 |
important role | 88 |
small intestine | 87 |
human beings | 87 |
syndrome coronavirus | 87 |
may lead | 87 |
new zealand | 86 |
interest reported | 86 |
body condition | 86 |
cell cultures | 85 |
nonhuman primates | 85 |
bacterial infections | 84 |
red pulp | 83 |
fever virus | 82 |
necrosis factor | 82 |
life cycle | 82 |
cell tumors | 82 |
significantly higher | 82 |
nile virus | 82 |
incubation period | 81 |
also known | 81 |
potential concern | 81 |
central nervous | 81 |
whole blood | 81 |
red blood | 81 |
mongolian gerbil | 80 |
high levels | 80 |
two groups | 80 |
monoclonal antibodies | 80 |
orogastric lavage | 80 |
whenever possible | 80 |
animal production | 80 |
activated charcoal | 80 |
world health | 79 |
kg po | 79 |
pulmonary edema | 79 |
staphylococcus aureus | 78 |
gene therapy | 78 |
also may | 78 |
health organization | 77 |
animals will | 77 |
equine encephalitis | 77 |
antibiotic resistance | 77 |
see section | 77 |
viral diarrhea | 76 |
cell line | 76 |
multiple organ | 76 |
health status | 76 |
monoclonal antibody | 76 |
mg dl | 76 |
meriones unguiculatus | 75 |
epithelial cells | 75 |
mouse model | 75 |
spinal cord | 75 |
also occur | 75 |
vaccine potency | 75 |
ebola virus | 75 |
severe cases | 75 |
rabies virus | 75 |
biomedical research | 74 |
standard requirements | 74 |
young animals | 74 |
control group | 74 |
heart failure | 73 |
immunodeficient mice | 73 |
septic patients | 73 |
salmonella spp | 73 |
large numbers | 73 |
hemorrhagic fever | 73 |
within days | 73 |
disease virus | 73 |
chain reaction | 72 |
animal care | 72 |
foreign bodies | 72 |
stem cells | 72 |
emerging infectious | 72 |
polymerase chain | 72 |
electron microscopy | 72 |
necropsy findings | 72 |
highly pathogenic | 71 |
supplemental assay | 71 |
human cases | 71 |
antibiotic therapy | 70 |
mortem inspection | 70 |
intravenous fluids | 70 |
tumor necrosis | 70 |
assay method | 70 |
side effects | 69 |
urinary tract | 69 |
encephalitis virus | 69 |
cynomolgus macaques | 69 |
viral replication | 69 |
sendai virus | 68 |
large number | 68 |
dairy calves | 68 |
viral rna | 67 |
severe disease | 67 |
alternative methods | 67 |
mammary gland | 67 |
food animals | 67 |
control measures | 66 |
cardiac output | 66 |
definitive diagnosis | 66 |
producing animals | 66 |
closely related | 66 |
mm hg | 66 |
secondary bacterial | 65 |
naturally occurring | 65 |
based tourism | 65 |
health care | 65 |
food animal | 65 |
anterior chamber | 64 |
passive immunity | 64 |
high risk | 64 |
supportive care | 64 |
diarrhea virus | 64 |
skin lesions | 64 |
increased risk | 64 |
metabolic acidosis | 63 |
control animals | 63 |
lymphoid tissue | 63 |
disseminated intravascular | 63 |
pathogenic vtec | 63 |
experimental infection | 63 |
may require | 62 |
intravascular coagulation | 62 |
antibiotic use | 62 |
hendra virus | 62 |
abdominal pain | 62 |
wide range | 62 |
infected mice | 62 |
one study | 62 |
cell types | 62 |
experimentally infected | 62 |
companion animal | 62 |
amino acids | 62 |
recent years | 61 |
canine distemper | 61 |
widely used | 61 |
modified live | 61 |
will also | 61 |
within hours | 61 |
east respiratory | 61 |
fatty acids | 60 |
nitric oxide | 60 |
united kingdom | 60 |
milk replacer | 60 |
immunodeficiency virus | 60 |
clinical symptoms | 60 |
developing countries | 60 |
virus isolation | 59 |
supplemental oxygen | 59 |
diabetes mellitus | 59 |
chadox mers | 59 |
animal shelters | 59 |
oral cavity | 59 |
plasma levels | 58 |
mesenteric lymph | 58 |
inbred strains | 57 |
perfringens type | 57 |
foreign body | 57 |
nucleic acid | 57 |
plasma cells | 57 |
human consumption | 56 |
pasteurella multocida | 56 |
small animals | 56 |
significant differences | 56 |
per day | 56 |
south africa | 56 |
significant difference | 56 |
neutralizing antibodies | 56 |
scientific opinion | 56 |
amino acid | 56 |
mononuclear cells | 55 |
contam panel | 55 |
fluid therapy | 55 |
clinical trial | 55 |
infectious virus | 55 |
white blood | 55 |
human infection | 55 |
human medicine | 55 |
may appear | 55 |
arterial blood | 54 |
serum samples | 54 |
many cases | 54 |
mongolian gerbils | 54 |
older animals | 54 |
viral diseases | 54 |
cell lymphoma | 54 |
become infected | 54 |
cov infection | 54 |
mortality rate | 53 |
determine whether | 53 |
bovine tuberculosis | 53 |
viral infection | 53 |
gross lesions | 53 |
adult mice | 53 |
pathologic findings | 52 |
domestic cats | 52 |
veterinary vaccine | 52 |
sars coronavirus | 52 |
may help | 52 |
environmental conditions | 52 |
dairy cattle | 52 |
lymphocytic choriomeningitis | 52 |
mouse strains | 52 |
per year | 52 |
mg ml | 52 |
blood vessels | 52 |
infection may | 51 |
intestinal tract | 51 |
diagnostic tests | 51 |
drug delivery | 51 |
persistent infection | 51 |
lung tissue | 51 |
dengue virus | 51 |
mice infected | 51 |
general anesthesia | 51 |
welfare conditions | 51 |
lyme disease | 51 |
bacterial infection | 51 |
may become | 51 |
nasal discharge | 51 |
health hazards | 51 |
council directive | 51 |
significantly increased | 50 |
healthy dogs | 50 |
compliant results | 50 |
statistically significant | 50 |
lymphoid tissues | 50 |
disease progression | 49 |
gene expression | 49 |
cause severe | 49 |
animal disease | 49 |
marginal zone | 49 |
heterocephalus glaber | 49 |
wound healing | 49 |
hong kong | 49 |
causative agent | 49 |
hair coat | 49 |
long term | 49 |
day post | 48 |
disease emergence | 48 |
research council | 48 |
immune function | 48 |
animals infected | 48 |
environmental factors | 48 |
dairy cows | 48 |
biological hazards | 48 |
rhesus monkeys | 48 |
significantly reduced | 48 |
type i | 48 |
disease caused | 48 |
close contact | 48 |
rheumatoid arthritis | 48 |
venezuelan equine | 48 |
working group | 48 |
pleural effusion | 47 |
data suggest | 47 |
induce emesis | 47 |
infrared thermography | 47 |
european union | 47 |
carbon dioxide | 47 |
type ii | 47 |
even though | 47 |
rabies vaccine | 47 |
food production | 47 |
hemorrhagic shock | 47 |
specific antibodies | 47 |
transgenic mice | 47 |
kg day | 47 |
immunosorbent assay | 47 |
laboratory mouse | 47 |
different types | 47 |
several weeks | 47 |
linked immunosorbent | 47 |
least one | 46 |
disease may | 46 |
antibiotic treatment | 46 |
risk factor | 46 |
disease transmission | 46 |
clostridium perfringens | 46 |
high mortality | 46 |
skeletal muscle | 46 |
vitro potency | 46 |
mouse models | 46 |
lesions may | 46 |
gram negative | 46 |
poor welfare | 45 |
individual animals | 45 |
directive ec | 45 |
laboratory rodents | 45 |
persistently infected | 45 |
adhesion molecules | 45 |
domestic animal | 45 |
veterinary public | 45 |
cause disease | 45 |
cell surface | 45 |
different species | 45 |
common cause | 44 |
may contribute | 44 |
farm animal | 44 |
intensive care | 44 |
treated animals | 44 |
veterinary services | 44 |
previously described | 44 |
perform orogastric | 44 |
safety testing | 44 |
monkeypox virus | 44 |
bl mice | 44 |
several studies | 44 |
animal use | 44 |
live animals | 44 |
animal feed | 44 |
mice may | 44 |
workshop participants | 44 |
chronic disease | 44 |
laboratory rats | 44 |
virus vaccine | 44 |
mycobacterium bovis | 44 |
two different | 44 |
administer intravenous | 43 |
influenza viruses | 43 |
wet markets | 43 |
blood loss | 43 |
signs may | 43 |
quality assurance | 43 |
tissue damage | 43 |
statistical analysis | 43 |
soft tissue | 43 |
hepatitis virus | 42 |
total body | 42 |
gene transfer | 42 |
human transmission | 42 |
also used | 42 |
animal cell | 42 |
small ruminant | 42 |
fatality rate | 42 |
virus infections | 42 |
wide variety | 42 |
campylobacter spp | 42 |
recent studies | 42 |
national research | 42 |
bite wounds | 42 |
lesions include | 42 |
group housing | 42 |
leukemia virus | 42 |
adverse effects | 41 |
significant increase | 41 |
intraocular pressure | 41 |
individual animal | 41 |
performed using | 41 |
skin scrapings | 41 |
tract infection | 41 |
mammary tumors | 41 |
urinary bladder | 41 |
time points | 41 |
goat production | 41 |
neutralizing antibody | 41 |
health problems | 41 |
often used | 41 |
large amounts | 41 |
total number | 41 |
animal studies | 41 |
new york | 41 |
zealand white | 41 |
smooth muscle | 40 |
animal abuse | 40 |
respiratory infections | 40 |
aqueous humor | 40 |
surface area | 40 |
growth factor | 40 |
complete blood | 40 |
crystalloid fluids | 40 |
intermediate host | 40 |
critically ill | 40 |
disease process | 40 |
infectious bovine | 40 |
passive transfer | 40 |
zoonotic pathogens | 40 |
organ dysfunction | 40 |
vascular spaces | 40 |
systemic inflammatory | 40 |
acute pancreatitis | 40 |
live virus | 40 |
signs associated | 40 |
gauge needle | 39 |
human vaccines | 39 |
domestic violence | 39 |
case fatality | 39 |
animals treated | 39 |
less common | 39 |
lung injury | 39 |
several days | 39 |
low levels | 39 |
growth factors | 39 |
liver enzymes | 39 |
past years | 39 |
antibody titers | 39 |
pet ownership | 39 |
lower respiratory | 39 |
neurologic signs | 39 |
retinal degeneration | 39 |
veterinary profession | 39 |
farm level | 39 |
antibody response | 39 |
vaccine development | 39 |
treatment consists | 39 |
social workers | 39 |
lymphatic vessels | 39 |
respiratory rate | 39 |
three times | 38 |
long periods | 38 |
scid mice | 38 |
high prevalence | 38 |
test results | 38 |
mechanical ventilation | 38 |
borne diseases | 38 |
days postinfection | 38 |
pseudomonas aeruginosa | 38 |
another study | 38 |
best interests | 38 |
kg hour | 38 |
mast cells | 38 |
weight gain | 38 |
viral disease | 38 |
first time | 38 |
group i | 38 |
farming systems | 38 |
single dose | 38 |
one animal | 38 |
thermal injury | 38 |
yellow fever | 38 |
human diseases | 38 |
south america | 37 |
early stages | 37 |
management practices | 37 |
pulp vascular | 37 |
interstitial pneumonia | 37 |
nonhuman primate | 37 |
human animals | 37 |
respiratory signs | 37 |
results indicate | 37 |
milk production | 37 |
blood count | 37 |
canine parvovirus | 37 |
intravenous catheter | 37 |
blood glucose | 37 |
research setting | 37 |
tissue culture | 37 |
live animal | 37 |
days later | 37 |
human population | 37 |
will increase | 37 |
helicobacter spp | 37 |
kg minute | 37 |
animal science | 37 |
large animals | 37 |
life span | 37 |
chain information | 37 |
burn injury | 37 |
milk replacers | 37 |
drinking water | 37 |
tested positive | 37 |
high doses | 37 |
naturally infected | 37 |
bordetella bronchiseptica | 37 |
chemical residues | 36 |
immunocompetent mice | 36 |
toxic effects | 36 |
endothelial cell | 36 |
human vaccine | 36 |
animal populations | 36 |
antimicrobial agents | 36 |
experimental animals | 36 |
current meat | 36 |
animal practice | 36 |
body fluids | 36 |
cotton rats | 36 |
environmental enrichment | 36 |
venous blood | 36 |
mouse colonies | 36 |
clinical sign | 36 |
underlying cause | 36 |
choriomeningitis virus | 36 |
significantly lower | 36 |
will help | 36 |
united nations | 36 |
may play | 36 |
calves fed | 36 |
regional lymph | 36 |
large animal | 36 |
international trade | 36 |
animal origin | 36 |
survival time | 36 |
clinical course | 36 |
make sure | 36 |
proinflammatory cytokines | 36 |
intravascular hemolysis | 36 |
iron deficiency | 35 |
common causes | 35 |
human infections | 35 |
livestock production | 35 |
microscopic examination | 35 |
clostridium difficile | 35 |
also found | 35 |
chemical hazards | 35 |
rabies vaccines | 35 |
social work | 35 |
viral diarrhoea | 35 |
cell proliferation | 35 |
animals used | 35 |
health monitoring | 35 |
protective immunity | 35 |
mean age | 35 |
experimental models | 35 |
domestic rabbits | 35 |
bacterial translocation | 35 |
quality control | 35 |
pet owners | 35 |
vesicular stomatitis | 35 |
animal facility | 35 |
prairie dogs | 35 |
congestive heart | 35 |
bovine serum | 35 |
nasal swabs | 35 |
healthy animals | 35 |
days post | 35 |
lymphatic system | 35 |
cell count | 34 |
neurological signs | 34 |
animal research | 34 |
class ii | 34 |
systemic disease | 34 |
systematic review | 34 |
breeding colonies | 34 |
clinical illness | 34 |
syrian hamsters | 34 |
disease outbreaks | 34 |
domesticated animals | 34 |
recent study | 34 |
animal pathogens | 34 |
north american | 34 |
local anesthetic | 34 |
medically important | 34 |
factor viii | 34 |
prohibited substances | 34 |
flow cytometry | 34 |
endangered species | 34 |
bowel disease | 34 |
may provide | 34 |
gold nanoparticles | 34 |
cytokine production | 34 |
inbred strain | 34 |
less commonly | 34 |
bile duct | 34 |
severely affected | 34 |
bovine rhinotracheitis | 34 |
antigen quantification | 34 |
findings include | 33 |
negative bacteria | 33 |
central venous | 33 |
common clinical | 33 |
human populations | 33 |
kg im | 33 |
experimental studies | 33 |
better understanding | 33 |
complement fixation | 33 |
squamous cell | 33 |
small rodents | 33 |
food intake | 33 |
every hours | 33 |
host range | 33 |
animals within | 33 |
will often | 33 |
cellular immune | 33 |
mortality rates | 33 |
cell carcinoma | 33 |
viral shedding | 33 |
intravenous crystalloid | 33 |
dendritic cells | 33 |
genetically engineered | 33 |
otitis media | 33 |
process hygiene | 33 |
west africa | 33 |
disease surveillance | 33 |
animal workers | 33 |
will require | 33 |
mediated hemolytic | 33 |
adaptive immune | 33 |
acute infection | 32 |
virus replication | 32 |
sudden death | 32 |
may reveal | 32 |
clinical manifestations | 32 |
one hand | 32 |
host defense | 32 |
several months | 32 |
early detection | 32 |
blood supply | 32 |
intermediate hosts | 32 |
fluorescent antibody | 32 |
distress syndrome | 32 |
tract disease | 32 |
kidney cells | 32 |
may contain | 32 |
results suggest | 32 |
coronavirus infection | 32 |
thoracic radiographs | 32 |
reservoir hosts | 32 |
white pulp | 32 |
highly contagious | 32 |
human pathogens | 32 |
blood transfusion | 32 |
lassa fever | 32 |
mean arterial | 32 |
laboratory rabbits | 32 |
acute disease | 32 |
group ii | 32 |
tract infections | 32 |
body surface | 32 |
distemper virus | 31 |
hepatic failure | 31 |
main hazards | 31 |
affected area | 31 |
hydrogen peroxide | 31 |
zoonotic infections | 31 |
inflammatory cells | 31 |
pathogenic avian | 31 |
environmental contamination | 31 |
cd cd | 31 |
production systems | 31 |
peritoneal macrophages | 31 |
significantly different | 31 |
current study | 31 |
disease course | 31 |
health risks | 31 |
six months | 31 |
liver disease | 31 |
inflammatory bowel | 31 |
diagnostic testing | 31 |
host species | 31 |
cats may | 31 |
mitral valve | 31 |
also important | 31 |
laboratory setting | 31 |
blood transfusions | 31 |
respiratory system | 31 |
tnf production | 31 |
new world | 31 |
optic nerve | 31 |
zika virus | 31 |
cytopathic effect | 31 |
high dose | 31 |
higher risk | 31 |
th century | 31 |
male mice | 31 |
raw materials | 31 |
must also | 31 |
virus type | 31 |
situ hybridization | 31 |
show signs | 31 |
urine output | 31 |
peritoneal cavity | 31 |
high incidence | 31 |
foodborne pathogens | 31 |
viral load | 30 |
crispr cas | 30 |
three groups | 30 |
will vary | 30 |
growth promoters | 30 |
goat meat | 30 |
corneal dystrophy | 30 |
resistant bacteria | 30 |
emerging diseases | 30 |
may vary | 30 |
commonly found | 30 |
urinary catheter | 30 |
disease prevention | 30 |
patients undergoing | 30 |
oxygen delivery | 30 |
suckling mice | 30 |
sterile saline | 30 |
renal tubular | 30 |
animal may | 30 |
normal values | 30 |
lawsonia intracellularis | 30 |
preventive measures | 30 |
blood volume | 30 |
vaccine safety | 30 |
younger animals | 30 |
intestinal mucosa | 30 |
future directions | 30 |
respiratory infection | 30 |
previously reported | 30 |
highly susceptible | 30 |
saline solution | 30 |
fatty acid | 30 |
risks associated | 30 |
iberian lynx | 30 |
faecal contamination | 30 |
animal experiments | 30 |
specific antibody | 30 |
blood smear | 30 |
meat products | 30 |
kidney disease | 30 |
rapid detection | 30 |
virus strain | 30 |
cellular immunity | 29 |
may induce | 29 |
inflammatory cytokines | 29 |
stem cell | 29 |
live vaccines | 29 |
crayfish plague | 29 |
tissue injury | 29 |
african green | 29 |
often associated | 29 |
survival rate | 29 |
retrospective study | 29 |
ag nps | 29 |
many countries | 29 |
high concentrations | 29 |
veterinary medical | 29 |
preventive approaches | 29 |
food security | 29 |
many different | 29 |
european commission | 29 |
renal function | 29 |
health surveillance | 29 |
streptobacillus moniliformis | 29 |
natural infection | 29 |
surgical procedures | 29 |
domestic cat | 29 |
sheep goats | 29 |
maternal antibodies | 29 |
resistant staphylococcus | 29 |
vaccination programs | 29 |
abdominal cavity | 29 |
occurs within | 29 |
endemic areas | 29 |
hematopoietic cells | 29 |
young calves | 29 |
toxicological profile | 29 |
drug administration | 29 |
renal disease | 29 |
newcastle disease | 29 |
jugular vein | 29 |
swine fever | 29 |
per animal | 29 |
immune cells | 29 |
feed intake | 29 |
time period | 29 |
neoplastic cells | 29 |
experimental inoculation | 29 |
made based | 29 |
fecal samples | 29 |
transgenic animals | 29 |
medicinal products | 29 |
may affect | 29 |
infant mice | 29 |
negative sepsis | 29 |
years ago | 29 |
climate change | 29 |
infectious agent | 28 |
innate immune | 28 |
receptor antagonist | 28 |
serologic tests | 28 |
red cell | 28 |
may produce | 28 |
intravenous fluid | 28 |
small number | 28 |
apache ii | 28 |
culture medium | 28 |
lethal infection | 28 |
husbandry practices | 28 |
fresh frozen | 28 |
zoonotic viruses | 28 |
also cause | 28 |
organ systems | 28 |
ml syringe | 28 |
may exhibit | 28 |
body mass | 28 |
nasal cavity | 28 |
frequently used | 28 |
novel coronavirus | 28 |
will continue | 28 |
major cause | 28 |
severe respiratory | 28 |
approximately days | 28 |
connective tissue | 28 |
female mice | 28 |
healthy volunteers | 28 |
poor prognosis | 28 |
may predispose | 28 |
animal husbandry | 28 |
data indicate | 28 |
european countries | 28 |
previous studies | 28 |
humoral immune | 28 |
many animals | 28 |
sodium bicarbonate | 28 |
immune status | 28 |
ill patients | 28 |
veterinary practice | 28 |
embryonic stem | 28 |
may need | 28 |
occur within | 28 |
livestock farming | 28 |
time pcr | 28 |
lethal disease | 28 |
significantly associated | 28 |
zoonotic potential | 28 |
infections may | 28 |
economic losses | 28 |
virus vaccines | 28 |
animal protection | 28 |
frozen plasma | 28 |
relative humidity | 28 |
white rabbits | 28 |
health importance | 28 |
viral vaccines | 28 |
may show | 28 |
mycoplasma pulmonis | 28 |
aspiration pneumonia | 27 |
nhp models | 27 |
bacterial pathogens | 27 |
cells may | 27 |
trauma patients | 27 |
animal consumption | 27 |
leptospira interrogans | 27 |
i i | 27 |
rabbit model | 27 |
serum biochemistry | 27 |
clinically normal | 27 |
spongiform encephalopathy | 27 |
wildlife species | 27 |
fatal disease | 27 |
first week | 27 |
multiple sclerosis | 27 |
usually occurs | 27 |
cardiac dysrhythmias | 27 |
nuclear transfer | 27 |
phase proteins | 27 |
flock herd | 27 |
diagnostic laboratory | 27 |
free radical | 27 |
carcinogenesis studies | 27 |
normal range | 27 |
disease occurs | 27 |
identifi ed | 27 |
human immunodeficiency | 27 |
small size | 27 |
zoonotic transmission | 27 |
cell type | 27 |
among others | 27 |
arterial pressure | 27 |
somatic cell | 27 |
virus transmission | 27 |
male dogs | 27 |
three different | 27 |
bite fever | 27 |
significantly decreased | 27 |
comparative study | 27 |
many species | 27 |
commonly affected | 27 |
many years | 27 |
lung lobes | 27 |
toxoplasma gondii | 27 |
reproductive tract | 27 |
muscle tremors | 27 |
oral route | 27 |
dose dependent | 27 |
clinical studies | 27 |
lamina propria | 27 |
catheter placement | 27 |
artificial insemination | 27 |
readily available | 27 |
different cell | 27 |
common marmosets | 27 |
platelet count | 27 |
south african | 27 |
two main | 27 |
autosomal recessive | 26 |
pathogenic bacteria | 26 |
emergency care | 26 |
effective treatment | 26 |
response syndrome | 26 |
may indicate | 26 |
oxide nanoparticles | 26 |
room temperature | 26 |
meat safety | 26 |
germinal centers | 26 |
animal rights | 26 |
diarrhoea virus | 26 |
diagnostic laboratories | 26 |
carrier animals | 26 |
internal medicine | 26 |
visual inspection | 26 |
first hours | 26 |
last years | 26 |
presumptive diagnosis | 26 |
marginal sinus | 26 |
scientific committee | 26 |
inflammatory mediators | 26 |
vascular access | 26 |
veterinary practices | 26 |
human exposure | 26 |
pneumocystis carinii | 26 |
potency tests | 26 |
cell lymphomas | 26 |
condition score | 26 |
southeast asia | 26 |
molecular biology | 26 |
blood sample | 26 |
animals must | 26 |
chemical substances | 26 |
samples taken | 26 |
wistar rats | 26 |
ruffled fur | 26 |
pulmonary artery | 26 |
commonly seen | 26 |
transmissible gastroenteritis | 26 |
less frequently | 26 |
kg body | 26 |
palm civets | 26 |
animal facilities | 26 |
antibody production | 26 |
shelter cats | 26 |
protective effect | 26 |
virus disease | 26 |
sheep goat | 25 |
preventive medicine | 25 |
bronchoalveolar lavage | 25 |
may increase | 25 |
affected dogs | 25 |
also available | 25 |
lymphoid cells | 25 |
heavy consumers | 25 |
maternal antibody | 25 |
carbon nanotubes | 25 |
surveillance systems | 25 |
exotic animals | 25 |
air quality | 25 |
may remain | 25 |
biological products | 25 |
tumor cells | 25 |
viral antigen | 25 |
adverse events | 25 |
small amount | 25 |
may involve | 25 |
raw meat | 25 |
reference standards | 25 |
athymic mice | 25 |
housing conditions | 25 |
warm water | 25 |
health service | 25 |
will result | 25 |
bovine herpesvirus | 25 |
recombinant human | 25 |
adult animals | 25 |
reverse transcriptase | 25 |
transmission occurs | 25 |
care unit | 25 |
acute renal | 25 |
cryptosporidium parvum | 25 |
pulmonary lesions | 25 |
bacterial diseases | 25 |
significant reduction | 25 |
welfare assessment | 25 |
cases may | 25 |
mouse strain | 25 |
rectal prolapse | 25 |
genome editing | 25 |
sick animals | 25 |
cancer cells | 25 |
positive results | 25 |
left ventricular | 25 |
described previously | 25 |
one group | 25 |
growth hormone | 25 |
surgical removal | 25 |
culture media | 25 |
chadox niv | 25 |
national institutes | 25 |
mammalian species | 25 |
blood smears | 25 |
veterinary use | 25 |
chadox gfp | 25 |
maintain hydration | 25 |
lymphoid organs | 25 |
indirect contact | 25 |
crocodilian species | 25 |
oxidative stress | 25 |
iv cri | 25 |
animals died | 25 |
future research | 25 |
metabolic rate | 25 |
blood gas | 25 |
potency test | 25 |
plasma concentrations | 25 |
small intestinal | 25 |
health approach | 25 |
new animals | 25 |
beef cattle | 25 |
regulatory authorities | 24 |
associated lymphoid | 24 |
infection occurs | 24 |
research studies | 24 |
vascular permeability | 24 |
takes place | 24 |
pet food | 24 |
two types | 24 |
serum biochemical | 24 |
varying degrees | 24 |
systemic antibiotics | 24 |
medicines within | 24 |
died within | 24 |
monitoring programmes | 24 |
statistical significance | 24 |
old world | 24 |
lymphoid follicles | 24 |
different animal | 24 |
small amounts | 24 |
rna viruses | 24 |
silica nanoparticles | 24 |
six animals | 24 |
phase i | 24 |
therapy may | 24 |
van der | 24 |
term studies | 24 |
may take | 24 |
granulation tissue | 24 |
foot rot | 24 |
veterinary clinics | 24 |
stress response | 24 |
occupational health | 24 |
lung lesions | 24 |
reluctant passenger | 24 |
surgical intervention | 24 |
transplantable tumors | 24 |
without clinical | 24 |
natural reservoir | 24 |
within weeks | 24 |
endotracheal tube | 24 |
european department | 24 |
diagnoses include | 24 |
embryo transfer | 24 |
detectable cases | 24 |
highly variable | 24 |
spectrum antibiotics | 24 |
es cells | 24 |
deficient mice | 24 |
calf welfare | 24 |
knockout mice | 24 |
contagious ecthyma | 24 |
provide information | 24 |
health professionals | 24 |
will develop | 24 |
chikungunya virus | 24 |
reactive protein | 24 |
will provide | 24 |
less likely | 24 |
often seen | 24 |
higher levels | 24 |
injection site | 24 |
breed dogs | 24 |
growth rate | 24 |
human contact | 24 |
veterinary epidemiology | 24 |
surveillance system | 24 |
diffi cult | 24 |
days postexposure | 23 |
environmental health | 23 |
currently available | 23 |
postmortem examination | 23 |
feline leukemia | 23 |
inspection procedures | 23 |
rat model | 23 |
disease severity | 23 |
migratory birds | 23 |
genital tract | 23 |
carrier state | 23 |
liver damage | 23 |
high percentage | 23 |
also seen | 23 |
human interface | 23 |
lymphoid lymphatic | 23 |
oryctolagus cuniculus | 23 |
usually associated | 23 |
infection control | 23 |
black disease | 23 |
spike protein | 23 |
young children | 23 |
measured using | 23 |
beta toxin | 23 |
lesser extent | 23 |
long time | 23 |
airway obstruction | 23 |
saudi arabia | 23 |
cerebral edema | 23 |
pathological changes | 23 |
small mammals | 23 |
control groups | 23 |
human primates | 23 |
virus may | 23 |
economic impact | 23 |
different strains | 23 |
clinical outcome | 23 |
electrolyte abnormalities | 23 |
pulmonary syndrome | 23 |
hantavirus pulmonary | 23 |
general population | 23 |
four weeks | 23 |
chronic infection | 23 |
nutritional support | 23 |
diagnostic methods | 23 |
japanese encephalitis | 23 |
mouse hepatitis | 23 |
genetically modified | 23 |
will need | 23 |
molecular weight | 23 |
goat kids | 23 |
infected rabbits | 23 |
health programs | 23 |
gold standard | 23 |
nonsteroidal antiinflammatory | 23 |
serum levels | 23 |
pi animals | 23 |
inflammatory reaction | 23 |
silver nanoparticles | 23 |
portal vein | 23 |
pulse oximetry | 23 |
scoring system | 23 |
edible tissues | 23 |
current status | 23 |
low prevalence | 23 |
bovine colostrum | 23 |
pale mucous | 23 |
wild rodents | 23 |
pregnancy toxemia | 23 |
genome sequence | 23 |
member states | 23 |
per group | 23 |
contaminated food | 23 |
platelet function | 23 |
zn nps | 23 |
growth performance | 22 |
days following | 22 |
high level | 22 |
commonly reported | 22 |
haemoglobin levels | 22 |
specific pathogen | 22 |
primate model | 22 |
contaminated feed | 22 |
eastern equine | 22 |
tissue sections | 22 |
large enough | 22 |
infection causes | 22 |
calf farming | 22 |
underlying disease | 22 |
days prior | 22 |
wildlife consumption | 22 |
general health | 22 |
capillary refill | 22 |
respiratory diseases | 22 |
genetic material | 22 |
associated infections | 22 |
green monkeys | 22 |
inspection service | 22 |
tgev antigen | 22 |
surgical excision | 22 |
neurological disease | 22 |
enteric pathogens | 22 |
fruit bats | 22 |
food products | 22 |
much higher | 22 |
wild birds | 22 |
cell responses | 22 |
many people | 22 |
will depend | 22 |
sepsis syndrome | 22 |
potency assay | 22 |
effective means | 22 |
heart disease | 22 |
influenza infection | 22 |
mucosal disease | 22 |
also affect | 22 |
therapeutic agents | 22 |
prothrombin time | 22 |
severe clinical | 22 |
also occurs | 22 |
like particles | 22 |
refill time | 22 |
treatment may | 22 |
normal dogs | 22 |
studies using | 22 |
iu kg | 22 |
australian veterinary | 22 |
plasma cell | 22 |
pcr assay | 22 |
mediated immunity | 22 |
abdominal ultrasound | 22 |
acral lick | 22 |
cynomolgus monkeys | 22 |
also present | 22 |
mus musculus | 22 |
may present | 22 |
hepatic necrosis | 22 |
several different | 22 |
data set | 22 |
genetic diversity | 22 |
antibody responses | 22 |
live attenuated | 22 |
within minutes | 22 |
bile ducts | 22 |
experimental model | 22 |
toxicity studies | 22 |
vitro studies | 22 |
months old | 22 |
carotid artery | 22 |
first step | 22 |
renal perfusion | 22 |
rat mite | 22 |
animal patients | 22 |
several times | 22 |
herpes simplex | 22 |
rural areas | 22 |
tissue samples | 22 |
ventricular dysrhythmias | 22 |
hypovolemic shock | 22 |
recombinant proteins | 22 |
aseptically scrub | 22 |
alligator mississippiensis | 22 |
significant correlation | 22 |
mammary glands | 22 |
assurance system | 22 |
emerging viruses | 22 |
law enforcement | 22 |
campylobacter jejuni | 22 |
kg sq | 22 |
plant health | 22 |
abdominal wall | 22 |
vaccine efficacy | 22 |
salivary glands | 22 |
veterinary association | 22 |
head tilt | 22 |
case study | 22 |
equi subsp | 22 |
calf serum | 22 |
see also | 22 |
vaginal discharge | 22 |
inbred mouse | 22 |
rectal temperature | 22 |
human use | 22 |
inbred mice | 22 |
congo hemorrhagic | 21 |
commonly associated | 21 |
nucleic acids | 21 |
pcr assays | 21 |
urban areas | 21 |
blood levels | 21 |
include fever | 21 |
infect humans | 21 |
findings suggest | 21 |
efsa panel | 21 |
low dose | 21 |
clinical findings | 21 |
parenteral nutrition | 21 |
western equine | 21 |
research institute | 21 |
cotton rat | 21 |
reperfusion injury | 21 |
interstitial fluid | 21 |
frequently reported | 21 |
gastrointestinal disease | 21 |
two weeks | 21 |
regulatory agencies | 21 |
liver failure | 21 |
animal shelter | 21 |
veterinary diagnostic | 21 |
fetal bovine | 21 |
internal organs | 21 |
almost always | 21 |
malignant tumors | 21 |
liver fluke | 21 |
study showed | 21 |
breeding colony | 21 |
natural killer | 21 |
body size | 21 |
zoonotic agents | 21 |
breeding season | 21 |
risk analysis | 21 |
animal cells | 21 |
hantaan virus | 21 |
streptococcus equi | 21 |
equine encephalomyelitis | 21 |
levels may | 21 |
every year | 21 |
inspection system | 21 |
case report | 21 |
chronic inflammatory | 21 |
commonly observed | 21 |
antigenic stimulation | 21 |
twice daily | 21 |
veterinary care | 21 |
safety evaluation | 21 |
several years | 21 |
kg bw | 21 |
antimicrobial therapy | 21 |
rat bite | 21 |
nrcp testing | 21 |
bovine spongiform | 21 |
human services | 21 |
also observed | 21 |
humoral immunity | 21 |
medium potential | 21 |
disease spread | 21 |
dark red | 21 |
human pathogenic | 21 |
mesoporous silica | 21 |
host response | 21 |
transgenic pigs | 21 |
dead animals | 21 |
animals showed | 21 |
section iii | 21 |
health issues | 21 |
virus challenge | 21 |
mineral oil | 21 |
broad spectrum | 21 |
mediated immune | 21 |
studies suggest | 21 |
clinical scores | 21 |
helicobacter hepaticus | 21 |
serological methods | 21 |
cns excitation | 21 |
true positive | 21 |
safety assurance | 21 |
cell volume | 21 |
urethral obstruction | 21 |
limited number | 21 |
animals vaccinated | 21 |
natural infections | 21 |
often present | 21 |
constant rate | 21 |
risk management | 21 |
chronic inflammation | 21 |
blood mononuclear | 21 |
research animals | 21 |
experimentally induced | 21 |
infected cats | 21 |
czech republic | 21 |
nodular hyperplasia | 21 |
ml min | 20 |
nonregenerative anemia | 20 |
will decrease | 20 |
will become | 20 |
large intestine | 20 |
evidence suggests | 20 |
serum albumin | 20 |
niv malaysia | 20 |
bluetongue virus | 20 |
hemorrhagic disease | 20 |
immune complexes | 20 |
animal population | 20 |
skin disease | 20 |
cardiovascular system | 20 |
cov strains | 20 |
health systems | 20 |
cut surface | 20 |
human patients | 20 |
protective equipment | 20 |
organ damage | 20 |
animals become | 20 |
ear canal | 20 |
chronically infected | 20 |
exposure assessment | 20 |
animal cruelty | 20 |
animal veterinary | 20 |
transmitted via | 20 |
susceptibility testing | 20 |
ad libitum | 20 |
large quantities | 20 |
iron oxide | 20 |
type diabetes | 20 |
cause acute | 20 |
animal relationships | 20 |
disease diagnosis | 20 |
pet animals | 20 |
trichophyton mentagrophytes | 20 |
animal interface | 20 |
viral loads | 20 |
important part | 20 |
international workshop | 20 |
sample collection | 20 |
alveolar macrophages | 20 |
one case | 20 |
blood sampling | 20 |
organ injury | 20 |
aerosol exposure | 20 |
day postexposure | 20 |
diseases caused | 20 |
animal tourism | 20 |
heat stress | 20 |
ethylene glycol | 20 |
reported cases | 20 |
left shift | 20 |
human respiratory | 20 |
neonatal mice | 20 |
also susceptible | 20 |
surgical treatment | 20 |
may serve | 20 |
remdesivir treatment | 20 |
housing systems | 20 |
global health | 20 |
short term | 20 |
residue monitoring | 20 |
heartworm disease | 20 |
will occur | 20 |
fluid volume | 20 |
day postinfection | 20 |
feline calicivirus | 20 |
litter size | 20 |
preclinical studies | 20 |
human rabies | 20 |
toxicity include | 20 |
adventitious viruses | 20 |
emerging disease | 20 |
inspection methods | 20 |
norwalk virus | 20 |
vaccinia virus | 20 |
clinical presentation | 20 |
rate infusion | 20 |
liver function | 20 |
clinical cases | 20 |
asymptomatic carriers | 20 |
family members | 20 |
heavy metals | 20 |
american alligators | 20 |
control program | 20 |
highly sensitive | 20 |
viral contaminations | 20 |
oncotic pressure | 20 |
information regarding | 20 |
cerebrospinal fluid | 20 |
hair loss | 20 |
body fat | 20 |
serum concentrations | 20 |
cortisol levels | 20 |
fasciola hepatica | 20 |
additional information | 20 |
well established | 20 |
defense mechanisms | 20 |
histiocytic sarcoma | 20 |
blood haemoglobin | 20 |
analgesic drugs | 20 |
also result | 20 |
tap water | 20 |
infection model | 20 |
animal contact | 20 |
abdominal palpation | 20 |
filovirus infection | 20 |
also reported | 20 |
therapeutic use | 20 |
fed milk | 20 |
alkaline phosphatase | 20 |
oxygen saturation | 20 |
medical treatment | 20 |
affected individuals | 20 |
septic complications | 20 |
multiple myeloma | 19 |
calves may | 19 |
great deal | 19 |
also common | 19 |
pilot study | 19 |
machine learning | 19 |
scientific veterinary | 19 |
data collection | 19 |
anterior segment | 19 |
urea nitrogen | 19 |
species may | 19 |
radiation therapy | 19 |
personal protective | 19 |
abdominal sepsis | 19 |
reference range | 19 |
may arise | 19 |
infected cells | 19 |
von willebrand | 19 |
including humans | 19 |
zone lymphoma | 19 |
commercial operations | 19 |
hepatocellular carcinoma | 19 |
often found | 19 |
good health | 19 |
years old | 19 |
secondary lymphoid | 19 |
nk cells | 19 |
first report | 19 |
patients without | 19 |
klebsiella pneumoniae | 19 |
results show | 19 |
per os | 19 |
genome sequencing | 19 |
factors associated | 19 |
species transmission | 19 |
protective antigen | 19 |
small intestines | 19 |
horseshoe bats | 19 |
third eyelid | 19 |
viral antigens | 19 |
zinc oxide | 19 |
help prevent | 19 |
risk categorisation | 19 |
also develop | 19 |
available data | 19 |
parainfluenza virus | 19 |
dogs may | 19 |
etiologic agent | 19 |
ulcerative dermatitis | 19 |
health problem | 19 |
taking care | 19 |
well tolerated | 19 |
source dogs | 19 |
hot water | 19 |
vena cava | 19 |
immune complex | 19 |
guangdong province | 19 |
vast majority | 19 |
wildlife conservation | 19 |
nutritional requirements | 19 |
macrophage system | 19 |
crystalloid fluid | 19 |
animals also | 19 |
current veterinary | 19 |
mycobacterium tuberculosis | 19 |
control seizures | 19 |
mental health | 19 |
federal regulations | 19 |
interrogans serovar | 19 |
reference values | 19 |
metal nanoparticles | 19 |
one third | 19 |
methods used | 19 |
predisposing factors | 19 |
tumor growth | 19 |
three days | 19 |
dawley rats | 19 |
hazards identified | 19 |
sentinel animals | 19 |
major role | 19 |
agriculture organization | 19 |
several factors | 19 |
new diseases | 19 |
significantly greater | 19 |
diarrheal disease | 19 |
animal markets | 19 |
large scale | 19 |
clinical features | 19 |
emerging zoonotic | 19 |
electrolyte imbalances | 19 |
rhesus macaque | 19 |
oral administration | 19 |
much less | 19 |
results demonstrate | 19 |
fluid pressure | 19 |
intercostal space | 19 |
social groups | 19 |
clostridium piliforme | 19 |
acute onset | 19 |
stomatitis virus | 19 |
close proximity | 19 |
plasma samples | 19 |
vary depending | 19 |
histopathological changes | 19 |
chronic cases | 19 |
negative results | 19 |
affected tissues | 19 |
toxic potential | 19 |
gastroprotectant drugs | 19 |
diaphragmatic hernia | 19 |
pox lesions | 19 |
experimental animal | 19 |
converting enzyme | 19 |
human monkeypox | 19 |
reservoir host | 19 |
sarcoptic mange | 19 |
daily basis | 19 |
cell death | 19 |
diagnosis diagnosis | 19 |
laboratory rat | 19 |
cause clinical | 19 |
hepatic encephalopathy | 19 |
one month | 19 |
states department | 19 |
major surgery | 19 |
lactic acidosis | 19 |
social contact | 19 |
one year | 19 |
salmonella typhimurium | 19 |
illicit use | 19 |
cell growth | 19 |
highly effective | 19 |
tetanus toxoid | 19 |
results obtained | 19 |
toxic dose | 19 |
weeks old | 19 |
log cfu | 18 |
catheter hub | 18 |
one another | 18 |
may allow | 18 |
pichinde virus | 18 |
among animals | 18 |
pv pa | 18 |
presenting cells | 18 |
various types | 18 |
used extensively | 18 |
veterinary therapy | 18 |
blood products | 18 |
perineal area | 18 |
listeria monocytogenes | 18 |
animal derived | 18 |
southern china | 18 |
lps challenge | 18 |
cell mass | 18 |
cause diarrhea | 18 |
disease complex | 18 |
especially important | 18 |
modifi ed | 18 |
borne transmission | 18 |
housed together | 18 |
severe sepsis | 18 |
will allow | 18 |
target cells | 18 |
mycoplasma spp | 18 |
least two | 18 |
wild mice | 18 |
young mice | 18 |
herd health | 18 |
increased respiratory | 18 |
systemic infection | 18 |
dead space | 18 |
adversely affect | 18 |
antiinflammatory drugs | 18 |
porcine islet | 18 |
develop clinical | 18 |
now available | 18 |
post infection | 18 |
much lower | 18 |
research facility | 18 |
brain tissue | 18 |
postmortem findings | 18 |
dogs used | 18 |
disease include | 18 |
caseous lymphadenitis | 18 |
animal agriculture | 18 |
studies indicate | 18 |
cytokine release | 18 |
minute virus | 18 |
samples collected | 18 |
found dead | 18 |
infection caused | 18 |
common bile | 18 |
initial treatment | 18 |
growth promotion | 18 |
health significance | 18 |
take place | 18 |
dog breeds | 18 |
main source | 18 |
standard deviation | 18 |
therapeutic efficacy | 18 |
mice develop | 18 |
final product | 18 |
supportive therapy | 18 |
extracellular matrix | 18 |
tracheal wash | 18 |
st century | 18 |
treat supportively | 18 |
veterinary science | 18 |
tailed deer | 18 |
pet dogs | 18 |
disease characterized | 18 |
developed countries | 18 |
lick granuloma | 18 |
streptococcus pneumoniae | 18 |
biomedical applications | 18 |
rodent species | 18 |
blood collection | 18 |
study reported | 18 |
virus strains | 18 |
provide adequate | 18 |
abdominal radiographs | 18 |
kupffer cells | 18 |
world primates | 18 |
often occurs | 18 |
serum igg | 18 |
rumen development | 18 |
feline infectious | 18 |
reactive oxygen | 18 |
vertical transmission | 18 |
secondary infection | 18 |
shed blood | 18 |
one species | 18 |
positive animals | 18 |
rabbits may | 18 |
interdigital cysts | 18 |
significantly elevated | 18 |
high potential | 18 |
supply chain | 18 |
animals develop | 18 |
basement membrane | 18 |
diagnostic tool | 18 |
animal control | 18 |
also include | 18 |
risk ranking | 18 |
stimulating factor | 18 |
corneal ulcers | 18 |
helicobacter species | 18 |
hunched posture | 18 |
bacterial growth | 18 |
unpublished data | 18 |
prevent infection | 18 |
hair follicles | 18 |
adenovirus type | 18 |
abomasal ulcers | 18 |
fisher scientific | 18 |
impression smears | 18 |
fecal flotation | 18 |
blood agar | 18 |
reference interval | 18 |
pasteurella pneumotropica | 18 |
horizontal transmission | 18 |
specific gravity | 18 |
reproductive performance | 18 |
techniques used | 18 |
animal movements | 18 |
cardiovascular disease | 17 |
proliferative enteropathy | 17 |
disease processes | 17 |
molecular characterization | 17 |
cultured cells | 17 |
relatively low | 17 |
burn wounds | 17 |
viral pathogens | 17 |
immune systems | 17 |
housed cats | 17 |
inflammatory responses | 17 |
occurs primarily | 17 |
integral part | 17 |
see chapters | 17 |
putorius furo | 17 |
pneumonia virus | 17 |
callithrix jacchus | 17 |
control programs | 17 |
economic model | 17 |
virus causes | 17 |
core temperature | 17 |
cell membrane | 17 |
mild cases | 17 |
associated virus | 17 |
ventricular tachycardia | 17 |
cytokine levels | 17 |
pancreatic duct | 17 |
lassa virus | 17 |
severe anemia | 17 |
dromedary camels | 17 |
poorly understood | 17 |
industrial vets | 17 |
clinically healthy | 17 |
serological evidence | 17 |
organisms may | 17 |
relatively small | 17 |
well known | 17 |
within hr | 17 |
three major | 17 |
third countries | 17 |
bacillary hemoglobinuria | 17 |
urban residents | 17 |
mustela putorius | 17 |
special attention | 17 |
subclinical infection | 17 |
progenitor cells | 17 |
tail docking | 17 |
significant role | 17 |
thermo fisher | 17 |
population density | 17 |
per minute | 17 |
common marmoset | 17 |
clinical surveillance | 17 |
producing escherichia | 17 |
research centre | 17 |
epidemiological studies | 17 |
mechanisms involved | 17 |
cats housed | 17 |
infected animal | 17 |
venous pressure | 17 |
abdominal distention | 17 |
skin infections | 17 |
porcine islets | 17 |
di giacomo | 17 |
hiv infection | 17 |
significant decrease | 17 |
ventral abdomen | 17 |
prospective study | 17 |
beef calves | 17 |
left atrial | 17 |
small numbers | 17 |
mild disease | 17 |
may explain | 17 |
scientific literature | 17 |
rate variability | 17 |
calves housed | 17 |
health risk | 17 |
borrelia burgdorferi | 17 |
frothy bloat | 17 |
similar results | 17 |
first days | 17 |
problems associated | 17 |
beneficial effects | 17 |
emerging zoonoses | 17 |
platelet aggregation | 17 |
will reduce | 17 |
study period | 17 |
bacterial pneumonia | 17 |
eye lesions | 17 |
elizabethan collar | 17 |
dairy herds | 17 |
serological tests | 17 |
fungal infections | 17 |
pregnant animals | 17 |
laboratory rabbit | 17 |
animal trade | 17 |
severe combined | 17 |
feed control | 17 |
take care | 17 |
virus neutralization | 17 |
brucella abortus | 17 |
thyroid hormone | 17 |
syphacia obvelata | 17 |
hip dysplasia | 17 |
cell activation | 17 |
microbiological safety | 17 |
adhesion molecule | 17 |
regulatory requirements | 17 |
mass spectrometry | 17 |
natural reservoirs | 17 |
may reduce | 17 |
cns depression | 17 |
antibody titer | 17 |
human sars | 17 |
harderian gland | 17 |
compliant samples | 17 |
abscess formation | 17 |
chronic pain | 17 |
disease outbreak | 17 |
water bottles | 17 |
decision making | 17 |
near future | 17 |
molecular epidemiology | 17 |
medical records | 17 |
cell population | 17 |
ex vivo | 17 |
dna synthesis | 17 |
oxidative damage | 17 |
breast cancer | 17 |
many diseases | 17 |
confirmed cases | 17 |
isothermal amplification | 17 |
fecal shedding | 17 |
production animals | 17 |
protective effects | 17 |
contaminated water | 17 |
professional expertise | 17 |
dairy herd | 17 |
particle size | 17 |
dna vaccine | 17 |
natural history | 17 |
virus outbreak | 17 |
low numbers | 17 |
american alligator | 17 |
rabies vaccination | 17 |
feedlot cattle | 17 |
also called | 17 |
lymphoid hyperplasia | 17 |
goats may | 17 |
first reported | 17 |
pasteurella haemolytica | 17 |
low concentrations | 17 |
less severe | 17 |
estrous cycle | 17 |
ii score | 17 |
three weeks | 17 |
magnetic resonance | 17 |
generally considered | 17 |
tropical rat | 17 |
care must | 17 |
replacement methods | 17 |
made available | 17 |
nutritional deficiencies | 17 |
cecal ligation | 17 |
fluorescein angiography | 17 |
health inspection | 17 |
endogenous retroviruses | 17 |
mhc class | 17 |
transmission may | 16 |
treatment groups | 16 |
chlamydia psittaci | 16 |
calculated using | 16 |
congenital defects | 16 |
consumed wild | 16 |
intact male | 16 |
laboratory findings | 16 |
neurologic disease | 16 |
coxiella burnetii | 16 |
intestinal contents | 16 |
may persist | 16 |
vaccine production | 16 |
teaching hospital | 16 |
bovine leukemia | 16 |
disease burden | 16 |
catarrhal fever | 16 |
clinical isolate | 16 |
erythroid hyperplasia | 16 |
serologic testing | 16 |
target species | 16 |
clinically affected | 16 |
dry matter | 16 |
muscular dystrophy | 16 |
susceptible animals | 16 |
upper airway | 16 |
niv bangladesh | 16 |
patients receiving | 16 |
vaccine manufacturers | 16 |
ectromelia virus | 16 |
binding protein | 16 |
live vaccine | 16 |
food consumption | 16 |
agricultural production | 16 |
antiviral activity | 16 |
infection include | 16 |
affected areas | 16 |
animals immunized | 16 |
also serve | 16 |
another important | 16 |
higher incidence | 16 |
low level | 16 |
protein synthesis | 16 |
capillary permeability | 16 |
following trauma | 16 |
veal calf | 16 |
disease symptoms | 16 |
feed materials | 16 |
production system | 16 |
population health | 16 |
also possible | 16 |
innate immunity | 16 |
viral contamination | 16 |
year period | 16 |
respiratory failure | 16 |
infected colonies | 16 |
may prevent | 16 |
personal communication | 16 |
disease associated | 16 |
food supply | 16 |
medical management | 16 |
cardiogenic shock | 16 |
antimicrobial use | 16 |
string suture | 16 |
malignant edema | 16 |
particular attention | 16 |
system may | 16 |
dog bite | 16 |
may represent | 16 |
kg per | 16 |
cho cells | 16 |
clot formation | 16 |
similar clinical | 16 |
real time | 16 |
two decades | 16 |
surgical patients | 16 |
vascular resistance | 16 |
test methods | 16 |
hind limb | 16 |
clinical syndromes | 16 |
humanized mice | 16 |
quarantine period | 16 |
corona virus | 16 |
microscopic lesions | 16 |
surgical trauma | 16 |
canine rabies | 16 |
free radicals | 16 |
patients suffering | 16 |
usually seen | 16 |
million people | 16 |
livestock species | 16 |
male rats | 16 |
undesirable substances | 16 |
molecular mechanisms | 16 |
blood cultures | 16 |
adult respiratory | 16 |
cell receptor | 16 |
transit time | 16 |
often difficult | 16 |
potential role | 16 |
antibiotics may | 16 |
inflammatory disease | 16 |
common findings | 16 |
cytologic examination | 16 |
new technologies | 16 |
type virus | 16 |
stainless steel | 16 |
first described | 16 |
literature review | 16 |
ornithonyssus bacoti | 16 |
fluid diuresis | 16 |
clinically relevant | 16 |
veterinary hospital | 16 |
adrenal gland | 16 |
vascular endothelium | 16 |
differ significantly | 16 |
soft tissues | 16 |
eu level | 16 |
total protein | 16 |
viral titers | 16 |
exploratory laparotomy | 16 |
adult sheep | 16 |
iv fluids | 16 |
production chain | 16 |
probably due | 16 |
recent advances | 16 |
two species | 16 |
great apes | 16 |
clostridial diseases | 16 |
rat trachea | 16 |
intestinal obstruction | 16 |
informed consent | 16 |
bacterial culture | 16 |
normal animals | 16 |
respiratory viruses | 16 |
largely supportive | 16 |
treatment includes | 16 |
partial hepatectomy | 16 |
gram positive | 16 |
red rubber | 16 |
signs occur | 16 |
studies showed | 16 |
inclusion bodies | 16 |
sars virus | 16 |
female dogs | 16 |
studies involving | 16 |
intranuclear inclusions | 16 |
hazards associated | 16 |
body wall | 16 |
beneficial effect | 16 |
quantification methods | 16 |
inflammatory lesions | 16 |
encephalomyelitis virus | 16 |
within normal | 16 |
times per | 16 |
land use | 16 |
lung lobe | 16 |
natural host | 16 |
proposed changes | 16 |
treatment options | 16 |
reference ranges | 16 |
also associated | 16 |
endogenous retrovirus | 16 |
intestinal parasites | 16 |
source attribution | 16 |
copper deficiency | 16 |
council regulation | 16 |
adult cats | 16 |
plasma endotoxin | 16 |
donor animals | 16 |
multiple trauma | 16 |
animal industry | 16 |
animals per | 16 |
key point | 16 |
valuable tool | 16 |
used successfully | 16 |
cas system | 16 |
mice developed | 16 |
wound management | 16 |
host immune | 16 |
clinical significance | 16 |
virus shedding | 16 |
chronic kidney | 16 |
oral vaccination | 16 |
human life | 16 |
large part | 16 |
two days | 16 |
induced arthritis | 16 |
helicobacter pylori | 16 |
muscle cells | 15 |
control programmes | 15 |
hematogenous spread | 15 |
pathogenic microorganisms | 15 |
female rats | 15 |
bred dogs | 15 |
wildlife health | 15 |
negative impact | 15 |
dairy goats | 15 |
health perspective | 15 |
porcine endogenous | 15 |
histological examination | 15 |
ophthalmic examination | 15 |
tnf levels | 15 |
wound closure | 15 |
fecal culture | 15 |
factor alpha | 15 |
ground squirrels | 15 |
calf production | 15 |
laboratory workers | 15 |
wound infection | 15 |
serum potassium | 15 |
border disease | 15 |
population wellness | 15 |
urine samples | 15 |
meat production | 15 |
lateral recumbency | 15 |
general public | 15 |
many tissues | 15 |
like coronaviruses | 15 |
microbiological status | 15 |
overall health | 15 |
mycobacterium avium | 15 |
frequently observed | 15 |
true negative | 15 |
external parasites | 15 |
one day | 15 |
housed calves | 15 |
organ system | 15 |
tumors may | 15 |
drug resistance | 15 |
ocular discharge | 15 |
positive correlation | 15 |
active ingredient | 15 |
cattle infected | 15 |
pressure sores | 15 |
dietary changes | 15 |
sodium chloride | 15 |
significantly less | 15 |
necrotic foci | 15 |
two animals | 15 |
recombinant dna | 15 |
hamster model | 15 |
identifi cation | 15 |
early stage | 15 |
coat color | 15 |
veterinary clinic | 15 |
include vomiting | 15 |
burn wound | 15 |
factors may | 15 |
borne disease | 15 |
respiratory droplets | 15 |
major histocompatibility | 15 |
adult worms | 15 |
cov replication | 15 |
diseased animals | 15 |
cattle herds | 15 |
procoagulant activity | 15 |
examination findings | 15 |
may therefore | 15 |
one hour | 15 |
important consideration | 15 |
administer supplemental | 15 |
animal bites | 15 |
wound contamination | 15 |
also provide | 15 |
acute pain | 15 |
human rights | 15 |
retinal detachment | 15 |
goat carcasses | 15 |
smaller ruminants | 15 |
relatively high | 15 |
pet insurance | 15 |
therapy products | 15 |
combined immunodeficiency | 15 |
slit lamp | 15 |
particularly important | 15 |
gel electrophoresis | 15 |
prevent disease | 15 |
veterinary surgeons | 15 |
vascular endothelial | 15 |
standing heat | 15 |
dog bites | 15 |
respiratory pattern | 15 |
mammalian cell | 15 |
clinical use | 15 |
animal waste | 15 |
peritoneal lavage | 15 |
higher among | 15 |
natural disease | 15 |
health concern | 15 |
amr problem | 15 |
subunit vaccine | 15 |
last decade | 15 |
median age | 15 |
rhinotracheitis virus | 15 |
serological testing | 15 |
infectious peritonitis | 15 |
flocks herds | 15 |
decreased production | 15 |
times higher | 15 |
cancer therapy | 15 |
concurrent disease | 15 |
white veal | 15 |
au nps | 15 |
norovirus infection | 15 |
mice inoculated | 15 |
clinical examination | 15 |
maternal immunity | 15 |
meq kg | 15 |
head trauma | 15 |
record keeping | 15 |
chronic stress | 15 |
new animal | 15 |
fetal calf | 15 |
salivary gland | 15 |
opportunistic infections | 15 |
protective efficacy | 15 |
laryngeal paralysis | 15 |
important source | 15 |
results showed | 15 |
combination therapy | 15 |
term survival | 15 |
malignant catarrhal | 15 |
mice also | 15 |
recent report | 15 |
median survival | 15 |
routine use | 15 |
dental disease | 15 |
complement system | 15 |
human sera | 15 |
slaughter hygiene | 15 |
highly virulent | 15 |
resonance imaging | 15 |
enteric disease | 15 |
imported animals | 15 |
annual cycle | 15 |
high morbidity | 15 |
cites listed | 15 |
uniform splenomegaly | 15 |
house mouse | 15 |
cell function | 15 |
viral vectors | 15 |
serum il | 15 |
diseases associated | 15 |
following major | 15 |
healthy controls | 15 |
contagious disease | 15 |
human cells | 15 |
endotoxin levels | 15 |
novel viruses | 15 |
electron microscopic | 15 |
mortem examination | 15 |
like symptoms | 15 |
murine norovirus | 15 |
common disease | 15 |
attitudes toward | 15 |
aerosol route | 15 |
intranasal inoculation | 15 |
fully understood | 15 |
corneal edema | 15 |
usually present | 15 |
data analysis | 15 |
surgical correction | 15 |
inflammatory process | 15 |
derived products | 15 |
cell carcinomas | 15 |
inhibitory effect | 15 |
us million | 15 |
carcass level | 15 |
infection also | 15 |
import records | 15 |
fl uid | 15 |
fusobacterium necrophorum | 15 |
packed cell | 15 |
water quality | 15 |
health implications | 15 |
like virus | 15 |
histocompatibility complex | 15 |
affected rabbits | 15 |
adaptation physiology | 15 |
health authorities | 15 |
well documented | 15 |
hours following | 15 |
carcinogenic potential | 15 |
typical clinical | 15 |
feline immunodeficiency | 15 |
animals received | 15 |
health system | 15 |
biosecurity measures | 15 |
health officials | 15 |
authors declare | 15 |
infected sheep | 15 |
wildlife diseases | 15 |
increased susceptibility | 15 |
usually subclinical | 15 |
disease signs | 15 |
disease risks | 15 |
increased vascular | 15 |
circulating blood | 15 |
anion gap | 15 |
taken together | 15 |
ambient temperature | 15 |
lethal dose | 15 |
similar disease | 15 |
aborted fetuses | 15 |
may influence | 15 |
producing cells | 15 |
nude mice | 15 |
elevated levels | 15 |
seven days | 15 |
histologic examination | 15 |
heavily contaminated | 15 |
bacterial contamination | 15 |
national institute | 15 |
pregnant women | 15 |
vector vaccine | 15 |
wellness program | 15 |
health program | 15 |
clotting factors | 15 |
veterinary teaching | 14 |
less virulent | 14 |
next generation | 14 |
also increases | 14 |
pulmonary disease | 14 |
traumatic injury | 14 |
topical application | 14 |
worldwide distribution | 14 |
ear mites | 14 |
brain stem | 14 |
great britain | 14 |
serum chemistry | 14 |
emerging viral | 14 |
one must | 14 |
water consumption | 14 |
whereas others | 14 |
acute hemolytic | 14 |
acute inflammation | 14 |
also causes | 14 |
adenovirus vectors | 14 |
welfare issues | 14 |
passive surveillance | 14 |
individual housing | 14 |
inclusion criteria | 14 |
mammalian cells | 14 |
alveolar damage | 14 |
herpes virus | 14 |
increased levels | 14 |
experimental infections | 14 |
future studies | 14 |
extremely important | 14 |
see appendix | 14 |
occur secondary | 14 |
los angeles | 14 |
vitro assays | 14 |
increased serum | 14 |
postoperative day | 14 |
laboratory diagnosis | 14 |
canine infectious | 14 |
novyi type | 14 |
bacterins animals | 14 |
various organs | 14 |
felis silvestris | 14 |
ebola outbreak | 14 |
zoonotic bacterial | 14 |
avian species | 14 |
animal reservoirs | 14 |
four animals | 14 |
fecal contamination | 14 |
rat colonies | 14 |
viral particles | 14 |